Cytokinetics reported a net loss of $135.6 million for the first quarter of 2024, compared to a net loss of $131.3 million for the same period in 2023. The company's cash, cash equivalents, and investments totaled $634.3 million as of March 31, 2024. Key activities included advancing the aficamten development program, initiating enrollment in the CEDAR-HCM trial, and progressing CK-586 towards a Phase 2 clinical trial.